Tacrines as Therapeutic Agents for Alzheimer's Disease. V. Recent Developments

被引：20

作者：

Bautista-Aguilera, Oscar M. ^{[1
]}

Ismaili, Lhassane ^{[2
]}

Iriepa, Isabel ^{[1
,3
]}

Diez-Iriepa, Daniel ^{[1
]}

Chabchoub, Fakher ^{[4
]}

Marco-Contelles, Jose ^{[5
]}

Perez, Marta ^{[6
]}

机构：

[1] Univ Alcala, Dept Quim Organ & Quim Inorgan, Ctra Madrid Barcelona,Km 33,6, Madrid 28871, Spain

[2] Univ Bourgogne Franche Comte, Lab Chim Organ & Therapeut, Neurosci Integrat & Clin EA 481, UFR Sante, 19 Rue Ambroise Pare, F-25000 Besancon, France

[3] Alcala Univ, Inst Chem Res Andres M del Rio, Madrid 28805, Spain

[4] Univ Sfax, Lab Chim Appl Heterocycles Corps Gras & Polymeres, Fac Sci Sfax, BP 802, Sfax 3000, Tunisia

[5] CSIC, Lab Med Chem IQOG, Juan de la Cierva 3, Madrid 28006, Spain

[6] Univ Basque Country, Publ Hlth Dept, Fac Med & Nursing, Leioa, Spain

来源：

CHEMICAL RECORD | 2021年 / 21卷 / 01期

关键词：

Alzheimer' s disease; Cholinesterase inhibition; Friedlä nder reaction; Hepatotoxicity; Tacrine derivatives; BIOLOGICAL ASSESSMENT; DIRECTED LIGANDS; SENILE DEMENTIA; ACETYLCHOLINESTERASE; INHIBITORS; DRUGS; FLUORESCEIN; MELATONIN; HYBRIDS; DESIGN;

D O I：

10.1002/tcr.202000107

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Herein we have reviewed our recent developments for the identification of new tacrine analogues for Alzheimer's disease (AD) therapy. Tacrine, the first cholinesterase inhibitor approved for AD treatment, did not stop the progression of AD, producing only some cognitive improvements, but exhibited secondary effects mainly due to its hepatotoxicity. Thus, the drug was withdrawn from the clinics administration. Since then, many publications have described non-hepatotoxic tacrines, and in addition, important efforts have been made to design multitarget tacrines by combining their cholinesterase inhibition profile with the modulation of other biological targets involved in AD.

引用

页码：162 / 174

页数：13

共 50 条

[41] MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents?
Angelucci, Francesco
Cechova, Katerina
Valis, Martin
Kuca, Kamil
Zhang, Bing
Hort, Jakub
[J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
[42] Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease
Golde, TE
Eriksen, JL
Weggen, S
Sagi, SA
Koo, EH
[J]. DRUG DEVELOPMENT RESEARCH, 2002, 56 (03) : 415 - 420
[43] SOME RECENT DEVELOPMENTS OF THE DOCTRINE OF COLLEN v. WRIGHT
Radcliffe, Francis R. Y.
[J]. LAW QUARTERLY REVIEW, 1902, 18 (72): : 364 - 375
[44] A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease
Kashif, Mohd.
Sivaprakasam, Prathibha
Vijendra, Poornima
Waseem, Mohammad
Pandurangan, Ashok Kumar
[J]. CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (43) : 3428 - 3441
[45] Neuropsychology of Alzheimer's disease.
Traykov, L
Marcie, P
Dalla Barba, G
Boller, F
[J]. REVUE NEUROLOGIQUE, 1999, 155 : 4S38 - 4S43
[46] Homocysteine and Alzheimer's disease.
Doyle, RM
Buggy, F
Bruce, I
Fallon, C
Eustace, A
Smith, O
McPartlin, J
Scott, J
Walsh, JB
Coakley, D
[J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S150 - S150
[47] Endocrinology and Alzheimer's disease.
Eber, O
[J]. NEUROPSYCHIATRIE, 1996, 10 (03): : 128 - 133
[48] The person with Alzheimer's disease.
Page, S
[J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 (06) : 560 - 560
[49] Early Alzheimer's Disease.
Mayeux, Richard
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (23): : 2194 - 2201
[50] A case of Alzheimer's disease.
Fuller, SC
[J]. ZEITSCHRIFT FUR DIE GESAMTE NEUROLOGIE UND PSYCHIATRIE, 1912, 11 : 158 - 172

← 1 2 3 4 5 →